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Open access undThe optimal management of brain metastases remains controversial. Both whole brain radiotherapy
(WBRT) and local treatment [surgery (S) or radiosurgery (RS)] are the cornerstones of treatment. The role
of systemic therapy is also being explored. Randomized controlled trials (RCT) have tried to assess the
individual and combined effects of different therapeutic strategies.
(1) RCT in oligometastatic patients: WBRT alone vs. local treatment + WBRT. Combined treatment may
improve both overall survival and local control in patients with a single metastasis, but it also leads to
a local control beneﬁt in patients with two to four lesions.
Exclusive local treatment vs.WBRT plus local treatment. The addition ofWBRT to local treatmentmay result
in improved local control, improved freedom from new brainmetastases and improved overall brain control.
S + WBRT vs. RS + WBRT. There is no evidence of superiority of a combined treatment over the other one.
(2) RCT addressing the point of improving WBRT outcome: differences inWBRT fractionation do not signif-
icantly alter outcome of treatments. Only a few systemic drugs may cause some signiﬁcant advantages.
(3) RCT that assessed neurocognitive impairment and quality of life: the baseline cognitive performance of
most patients is signiﬁcantly impaired. Intracranial tumor control is an essential factor in stabilizing neu-
rocognitive function. The data on neurocognitive toxicity related to WBRT are still contradictory. Impair-
ment of both neurocognitive function and quality of life of patients with brain metastases needs to be
further addressed in RCT.
 2011 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 102 (2012) 168–179Brain metastases develop in up to 30% of patients with cancer
[1]. With the best supportive care, median survival time is 1–
2 months [2]. The cornerstones of treatment are surgery (S), whole
brain radiotherapy (WBRT), and radiosurgery (RS) [3]. The chances
of using a local therapy (S or RS) depend on the number, the size,
and the site of brain lesions. The main prognostic factors for pa-
tients with brain metastases are Karnofsky performance status
(KPS) (P70 vs. <70), age (<65 vs.P65 years), control of primary tu-
mor, absence of extracranial metastases, and number of brain le-
sions. All of these factors, except for number of brain metastases,
are included in the Recursive Partitioning Analysis (RPA) classiﬁca-
tion [4]. Sperduto et al. [5], analyzing more than 4200 patients with
newly diagnosed brain metastases, found that the signiﬁcance of
prognostic factors varied by the primary tumor; consequently, no
single prognostic index might be appropriate for all patients with
brain metastases, and different prognostic factors should be
weighed differently in the clinical decision-making processes of
such a heterogeneous population.
It is worth noting that most of the patients treated for brain
metastases die of extracranial disease [6]. This is an importantology, Azienda Ospedaliero
nce, Italy.
anti).
er CC BY-NC-ND license.consideration because, although most studies have used overall
survival as the main endpoint, survival is probably not the best
parameter to measure the efﬁcacy of the existing therapeutic
modalities [7].Materials and methods
An extensive literature search was undertaken to identify pub-
lished randomized controlled trials (RCT) for brain metastases.
Data were identiﬁed by searching the PUBMED database using
the keywords ‘‘brain metastases’’, ‘‘randomized trial’’, ‘‘radiother-
apy’’, ‘‘whole brain radiation therapy’’, ‘‘radiosurgery’’, and ‘‘sur-
gery’’. Only papers published in English were included. Meeting
proceedings were used when they concerned RCT that had not
yet been published in full-text format. The results of the different
treatments in terms of brain tumor control (either local control
or freedom from new brain metastases), neurological death rate,
overall survival and quality of life were reported. All data were ex-
tracted and tabulated from the articles’ text, tables, and ﬁgures.
We divided our appraisal into three main issues. The ﬁrst issue
concerned RCT on oligometastatic patients, assessing the role of lo-
cal treatment with or without WBRT. The second issue consisted of
RCT addressing the point of improving WBRT outcome. The third
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and quality of life of patients with brain metastases.
The tables summarize the main results of the RCT issue by issue.
Results
Randomized controlled trials on oligometastatic patients
Several trials have assessed the role of a more aggressive com-
bined approach compared with WBRT alone in the management of
brain oligometastatic disease. Other trials have assessed the role of
WBRT as an adjuvant treatment after surgery or radiosurgery, com-
paring the combined approach with the exclusive local treatment.
These trials explored the possibility of WBRT withdrawal, based on
the rationale of avoiding putative neurotoxicity due to WBRT. The
results of a small trial that compared the combined treatment
(RS + WBRT vs. S + WBRT) for solitary brain metastases were re-
cently published.
WBRT alone vs. WBRT + local treatment (surgery or radiosurgery) in
patients with brain oligometastatic disease (Table 1)
WBRT vs. S + WBRT. The trial from Patchell et al. [8] showed that
surgical treatment of brain metastasis was related to a reduced
rate of recurrence at the original site of metastasis (p < 0.02), with
a longer local relapse-free survival (p < 0.0001), a longer survival
rate (p < 0.01), a longer functionally independent survival
(p < 0.005) and a lower risk of death from neurological causes
(p < 0.0009). Multivariate analysis showed that surgical treatment
of the brain metastasis was associated with increased survival
(p < 0.04), whereas the presence of disseminated disease and
increasing age were associated with decreased survival (p < 0.02
and p < 0.01, respectively).Table 1
Trials comparing whole brain radiotherapy vs. (whole brain radiotherapy + local treatmen
Author Treatment
arms
Prescribed dose n Inclusion
criteria
Local
contro
Patchell [8] WBRT WBRT: 36 Gy in
12 fr
48 Single lesion, all
the primaries
48.0%
S +WBRT WBRT: 36 Gy in
12 fr
80.0%
Vecht and
Noordijk
[9,10]
WBRT WBRT: 40 Gy in
20 fr b.i.d.
63 Single lesion, all
the primaries
n.a.
S + WBRT WBRT: 40 Gy in
20 fr b.i.d.
Mintz [11] WBRT WBRT: 30 Gy in 10
fr
84 Single lesion, all
the primaries
n.a.
S + WBRT WBRT: 30 Gy in 10
fr
Time t
failure
Kondziolka [12] WBRT WBRT: 30 Gy in 12
fr
27 2–4 lesions, all the
primaries
6 m
RS + WBRT RS: 16 Gy WBRT:
30 Gy in 12 fr
36 m
Andrews [13] WBRT WBRT: 37.5 Gy in
15 fr
331 1–3 lesions, all the
primaries
71.0%
RS + WBRT RS: <2 cm: 24 Gy;
2–3 cm:
18 Gy; 3–4 cm:
15 Gy
WBRT: 37.5 Gy in
15 fr
82.0%
S, surgery; WBRT, whole brain radiotherapy; RS, radiosurgery; fr, fractions; b.i.d., twice a
difference; BM, brain metastases.A Dutch trial [9,10] reported that survival was signiﬁcantly
longer for the combined treatment (S + RT) group than for the
radiotherapy group (p = 0.04). This beneﬁt was conﬁned to patients
with stable or absent extracranial disease (median survival 12 vs.
7 months, p = 0.02), whereas for patients with active disease, sur-
vival was equally poor (median survival of 5 months for both treat-
ment arms). Age was a strong prognostic factor: patients older
than 60 years had a hazard ratio (HR) of dying of 2.74 (p = 0.001)
compared with younger patients. In the younger patient group,
median survival was much better in the S + RT arm than in the
RT arm (19 vs. 9 months); in older patients, median survival was
poor and similar in both arms (6 vs. 5 months) [10]. Functionally
independent survival (deﬁned as WHO performance status 61
and neurological condition 61) was better for patients who were
treated with surgery and postoperative WBRT, without reaching
statistical signiﬁcance (p = 0.06).
On the contrary, Mintz et al. [11] did not ﬁnd any signiﬁcant
advantage in terms of median survival between patients random-
ized to WBRT alone and those who underwent S + WBRT (6.3 and
5.6 months, respectively; p = 0.24). There was no difference be-
tween the two arms in how long patients maintained functional
independence (KPS P70) or in terms of neurological death rate.
In summary, two of the three trials [8–10] show that the com-
bined approach (S + WBRT) improves treatment outcomes com-
pared with exclusive WBRT in patients with a single brain
metastasis. This beneﬁt is most pronounced for patients with
favorable prognostic factors.WBRT vs. RS + WBRT. Kondziolka et al. [12] randomized patients
with two to four brain lesions (maximum diameter 625 mm) to
WBRT alone or RS + WBRT. The trial was closed according to prede-
ﬁned stopping rules following an interim analysis that showed at).
l
Freedom from new
brain metastases
Brain tumor
control
Neurologic
death
Survival
Time to
neurologic
death
NS n.a. 26 w 3.6 m
62 w 9.5 m
n.a. n.a. NS 6.0 m
10.0 m
n.a. n.a. NS NS
o local Time to any
brain failure
n.a. 5 m n.a. NS
34 m
All Single
BM
n.a. NS NS NS 4.9 m
6.5 m
day; w, weeks; m, months; y, year; n.a., not available; NS, not statistically signiﬁcant
170 Randomized trials in brain metastasesstrong beneﬁt in brain tumor control for patients treated with
RS +WBRT. The rate of local failure at 1 year was 100% after WBRT
alone, but only 8% after RS + WBRT (p = 0.0016). Signiﬁcant differ-
ences were shown in terms of median time to both local failure
(p = 0.0005) and any brain failure (p = 0.002). No difference in over-
all survival was noted between the two groups (p = 0.22).
The Radiation Oncology Group (RTOG) 9508 trial randomly as-
signed patients with one to three brain metastases either to WBRT
or to WBRT followed by RS boost [13]. Maximum allowed diameter
was 4 cm for the largest lesion and 3 cm for the additional lesions.
Patients with KPS <70 were excluded.
The local control rate was superior for the RS arm (p = 0.01).
Surprisingly, higher radiosurgery doses were not related to better
control of the treated lesion. Patients with a solitary metastasis
who received radiosurgical boost had signiﬁcantly better survival
(p = 0.04), whereas survival did not differ between the treatment
arms for patients with two or three lesions (p = 0.97). It should
be noted that the difference in terms of median survival for single
metastasis was only 1.6 months (4.9 months for WBRT alone vs.
6.5 months for RS + WBRT). Patients in the RS armwere more likely
to have stable or improved KPS score at 6 months after treatment
than were patients treated exclusively with WBRT (p = 0.03). On
multivariate analysis, RPA class 1 resulted in a signiﬁcant prognos-
tic factor, independently of number of metastases. Multivariate
analysis indicated that RS + WBRT provided only a borderline sur-
vival beneﬁt to patients with a solitary lesion (p = 0.053). It is
worth nothing that no statistically signiﬁcant improvement in sur-
vival was found between patients treated with different treatment
units (Linac vs. Gammaknife) (p = 0.94). Early and late toxicity did
not differ between the two arms.
These two trials demonstrate that the addition of radiosurgery
improves local control [12–13] and functional autonomymeasured
by KPS [13] for oligometastatic patients. Furthermore, the RTOG
9508 trial suggests that the combined treatment (RS + WBRT)
may cause a slight improvement of survival for patients with a sol-
itary brain lesion.
Thus, it may be concluded from the results of these trials that
the addition of local treatment (S for single lesion, RS for one toTable 2
Trials comparing exclusive local therapy vs. (whole brain radiotherapy + local treatment.
Author Treatment
arms
Prescribed dose n Inclusion
criteria
Patchell [14] S – 95 Single
lesion
S + WBRT WBRT: 50,4 Gy in 28 fr All the
primaries
Aoyama [15] RS RS:62 cm: 22–25 Gy;>2 cm:
18–20 Gy
132 1–4
lesions
RS + WBRT RS: dose reduction by 30% All the
primariesWBRT: 30 Gy in 10 fr or 12 fr
Chang [16] RS RS:<2 cm: 18 Gy; 2–3 cm:
15 Gy; 3–4 cm: 12 Gy
58 1–3
lesions
RS + WBRT RS:<2 cm: 18 Gy; 2–3 cm:
15 Gy; 3–4 cm: 12 Gy
All the
primaries
WBRT: 30 Gy in 12 fr
Mueller and
Kocher [20,21]
RS or S RS: 20 Gy 359 1–3
lesions
RS or
S + WBRT
RS: 20 GyWBRT: 30 Gy in 10 fr All the
primaries
Roos [22] RS or S RS: n.a. 19 Single
lesion
RS or
S + WBRT
WBRT: 36 Gy in 18 fror 30 Gy
in 10 fr
All the
primaries
Muacevic [23] RS RS: mean dose 21 Gy (range
14–27 Gy)
64 Single
lesion
S + WBRT WBRT: 40 Gy in 20 fr All the
primaries
S, surgery; WBRT, whole brain radiotherapy; RS, radiosurgery; fr, fractions; w, weeks; mfour brain metastases) to WBRT might represent a superior treat-
ment modality in terms of improving local tumor control for oligo-
metastatic patients (n 6 4). For patients with a single metastasis,
the use of local treatment (S or RS) plus WBRT may result also in
a better survival, especially for patients with good prognostic
factors.
Exclusive local treatment (surgery for single brain lesion or
radiosurgery for 64 lesions) vs. WBRT + local treatment (surgery or
radiosurgery) (Table 2)
S vs. S + WBRT. In 1998, Patchell et al. [14] published the results of
a trial that compared exclusive surgery with surgery plus adjuvant
WBRT for patients with a solitary brain metastasis. Multivariate
analysis showed that postoperative WBRT was associated with a
lower risk of brain recurrence (p < 0.001), a reduced risk of devel-
oping recurrence of the original brain metastasis (p < 0.001) and
a lower rate of recurrence of distant brain metastasis (p = 0.02).
Although adjuvant radiotherapy prevented death due to neurolog-
ical causes (p = 0.003), the median survival was not signiﬁcantly
different. Furthermore, no signiﬁcant difference in terms of func-
tionally independent survival (deﬁned as time with KPS P70)
was found.RS vs. RS + WBRT. In a Japanese trial [15], 132 patients with one to
four brain metastases, each with a maximum diameter <3 cm, were
randomly assigned to receive RS alone or RS + WBRT. The multivar-
iate analysis demonstrated that RS + WBRT was associated with a
reduced risk of brain local recurrence (p < 0.001) and distant re-
lapse (p < 0.001). The authors did not ﬁnd any signiﬁcant difference
in terms of survival rate (1-year actuarial survival for RS alone,
28.4%; 1-year actuarial survival for RS + WBRT, 38.5%) and neuro-
logical death rate (RS alone, 19.3%; RS + WBRT, 22.8%). At
12 months the systemic functional preservation rates (KPS P70)
and actuarial rates of neurological preservation (i.e., any worsening
of the neurological performance) were not statistically different.
Symptomatic late neurological symptoms were reported in seven
patients in the RS +WBRT arm and in three cases in the radiosur-
gery arm (p = 0.20).Local
control
Freedom from new
brain metastases
Brain tumor
control
Neurologic
death rate
Survival
54.0% 63.0% 30.0% 44.0% NS
90.0% 86.0% 82.0% 14.0%
72.5% @
1 y
36.3% @ 1 y 23.6% @ 1 y NS NS
88.7% @
1 y
58.5% @ 1 y 53.2% @ 1 y
67.0% @
1y
45.0% @ 1y 27.0% @ 1y NS 15.2 m
100.0%
@ 1y
73.0% @ 1y 73.0% @ 1y 5.7 m
68.7% @
2 y
67.6% @ 2 y 46% @ 2y 44.0% NS
83.6% @
2 y
82.4% @ 2 y 68.6% @ 2 y 28.0%
n.a. n.a. NS n.a. NS
NS 74.2% @ 1 y n.a. NS NS
97.0% @ 1 y
, months; y, year; n.a., not available; NS, not statistically signiﬁcant difference.
S. Scoccianti, U. Ricardi / Radiotherapy and Oncology 102 (2012) 168–179 171In a recently, published trial, Chang et al. randomized 58 pa-
tients with one to three newly diagnosed brain metastases to
exclusive RS or RS + WBRT [16]. Although the primary endpoint
was neurocognitive assessment at 4 months, the authors also re-
ported the results in terms of tumor control: patients who were
treated with RS +WBRT had a signiﬁcant improvement in terms
of local tumor control (p = 0.012), distant brain tumor control
(p = 0.02), and freedom from central nervous system (CNS) recur-
rence (p = 0.0003). Surprisingly, higher survival was observed in
the RS group (p = 0.003). This survival advantage for the RS group
has been attributed to a meaningful imbalance of the study groups
in terms of prognostic factors and with strong differences in sal-
vage therapy between the two cohorts, with a more aggressive ap-
proach for patients treated with RS only [17–19].
S or RS vs. S or RS + WBRT. The recently closed European Organiza-
tion for Research and Treatment of Cancer (EORTC) 22952–26001
trial addressed the role of WBRT after local treatment, whatever
that treatment was (surgery or radiosurgery) [20,21]. After local
treatment, 359 patients with one to three brain metastases were
randomized for adjuvant WBRT (RS + WBRT, n = 99; S + WBRT,
n = 81) or observation (RS alone, n = 100; S alone, n = 79). Only pa-
tients with no or stable extracranial disease or with asymptomatic
synchronous primary tumor and with European Cooperative
Oncology Group (ECOG) performance score of 0–2 were eligible.
For radiosurgery, the maximum diameter of the brain lesion could
measure 3 cm for patients with single brain metastasis and 2.5 cm
for cases with two or three lesions. The prescribed marginal dose
was 20 Gy. No differences in survival or in the time period of func-
tional independence (i.e., time to ECOG PS deterioration to <2)
were found (HR = 0.98, p = 0.89, and HR = 0.96, p = 0.71, respec-
tively). Postsurgical WBRT reduced the probability of relapse at ini-
tial site (27% vs. 59%, p < 0.001), as well as at new sites (23% vs.
42%, p = 0.008). In patients who received WBRT after radiosurgery,
the progression rate both at the original site (19% vs. 31%, p = 0.04)
and at new sites (33% vs. 48%, p = 0.02) was reduced.
Another randomized trial evaluated adjuvant WBRT after sur-
gery or radiosurgery for single brain metastases [22]. The study
was prematurely suspended due to slow accrual after the enroll-
ment of 19 patients. There was no statistically signiﬁcant differ-
ence in terms of median CNS failure-free survival, median
progression-free survival, and median overall survival. Time to
deterioration of WHO performance status to >1 was not different
between the two arms. Although there was a trend toward reduced
CNS relapse with WBRT (30% for patients treated with combined
approach vs. 78% for patients treated with exclusive S or RS), the
difference was not signiﬁcant (p = 0.12). Considering the small
number of patients, the authors concluded that their results sup-
port the use of postoperative WBRT to improve CNS control.
RS vs. S + WBRT. Only one trial compared exclusive radiosurgery
with S + WBRT [23]. The combined treatment provided only a
superior brain distant control (p = 0.04), whereas local control (1-
year local control rate: 82% in the S + WBRT group and 96.8% inTable 3
Trial comparing combined therapy (S + whole brain radiotherapy vs. RS + WBRT).
Author Treatment arms Prescribed dose n Inclusion criteria Loc
Roos [24] S + WBRT WBRT: 30 Gy in 10 fr 21 Single lesion n.a
RS + WBRT RS:62 cm: 20 Gy; All the primaries
2.1–3.0 cm: 18 Gy;
3.1–4.0 cm: 15 Gy
WBRT: 30 Gy in 10 fr
S, surgery; WBRT, whole brain radiotherapy; RS, radiosurgery; fr, fractions; n.a., not avathe RS group), neurologic death rate, and survival did not signiﬁ-
cantly differ. There was no signiﬁcant difference in length of time
with stabilized or improved KPS. Treatment groups did not differ
in terms of late severe toxicity.
From the above-mentioned trials, it may be concluded that in
oligometastatic patients (n 6 4), class I evidence supports lower
rates of intracranial failure (both at the original site of the metas-
tasis and in the brain overall) when WBRT is added to local
treatment.
Comparison of combined treatments: WBRT + surgery vs.
WBRT + radiosurgery for solitary brain metastasis (Table 3)
Only one recently published randomized trial [24] was designed
to assess whether a combined approach with RS +WBRT is as
effective as S + WBRT for patients with a single brain lesion. The
trial was closed early due to slow accrual, mainly because few pa-
tients proved to be truly suitable for both treatment modalities (RS
or S). Even though no deﬁnitive conclusions can be drawn due to
the small number of patients (n = 21), no signiﬁcant differences
were found in terms of median overall survival (p = 0.20) or med-
ian failure-free survival time (p = 0.20).Randomized controlled trials addressing the point of improving
the WBRT outcome
Since the majority of patients with brain metastases are not po-
tential candidates for radiosurgery or neurosurgery due to the
number of lesions, tumor location, or performance status, WBRT
remains the standard treatment in most patients.
Thus, different total doses and fractionation schedules were
assessed in several RCT to improve the outcome of WBRT in
terms of survival or symptomatic effect. Another potential
approach to improve the beneﬁts of WBRT is the addition of
systemic therapy.
Comparison of different WBRT fractionation schedules (Table 4)
Between 1971 and 1976 the RTOG conducted two randomized
phase III trials to study the palliative effects of different fraction-
ation schemes. The ﬁrst study included 910 patients randomly as-
signed to four treatment arms (30 Gy in 2 or 3 weeks and 40 Gy in
3 or 4 weeks) [25]. The second study enrolled 902 patients ran-
domized to three treatment arms (20 Gy in 1 week, 30 Gy in
2 weeks, and 40 Gy in 3 weeks) [25]. Patients were considered inel-
igible only for recent changes in the patient’s anticancer treatment
and for factors that would prohibit adequate follow-up. No signif-
icant differences among treatment schedules were found with re-
spect to response rate, duration of improvement, palliative effect,
time to progression, and survival. The conclusions of these two
studies was that schedules such as 20 Gy in 1 week or 30 Gy in
2 weeks had the same effectiveness of schemes requiring higher
total doses over long periods.
Some institutions participated in a separate section of these
studies involving a randomization to ultrarapid high-doseal control Freedom from new
brain metastases
Brain tumor control Neurologic
death rate
Survival
. NS n.a n.a. NS
ilable; NS, not statistically signiﬁcant difference.
Table 4
Trials comparing different fractionation schedules of whole brain radiotherapy.
Author Treatment
arms
Prescribed dose n Inclusion criteria Brain tumor control Neurologic
death rate
Survival
Median time to progression
Borgelt [25] WBRT WBRT 30 Gy in 10 fr 910 – NS n.a. NS
WBRT WBRT 30 Gy in 15 fr
WBRT WBRT 40 Gy in 15 fr
WBRT WBRT 40 Gy in 20 fr
Median time to progression
Borgelt [25] WBRT WBRT 20 Gy in 5 fr 902 – NS n.a. NS
WBRT WBRT 30 Gy in 10 fr
WBRT WBRT 40 Gy in 15 fr
Borgelt [26] WBRT WBRT 30 Gy in 10 fr 138 – WBRT 10 Gy in one fr: shorter time
to progression and duration of
clinical improvement
NS NS
WBRT WBRT 30 Gy in 15 fr
WBRT WBRT 40 Gy in 15 fr
WBRT WBRT 40 Gy in 20 fr
WBRT WBRT 10 Gy in one fr
Borgelt [26] WBRT WBRT 20 Gy in 5 fr 64 – WBRT 20 Gy in 5 fr: shorter time to
progression
NS NS
WBRT WBRT 12 Gy in 2 fr
Median time to progression
Kurtz [27] WBRT WBRT 30 Gy in 10 fr 255 No evidence of extracranial metastases,
controlled primary tumor, neurologic
function classes I–III
NS NS NS
WBRT WBRT 50 Gy in 20 fr
Retreatment
Komarnicky
[28]
WBRT WBRT 30 Gy in 10 fr 393 KPS >40, age 18–75 y NS NS NS
WBRT WBRT 30 Gy in 6 fr
Haie-Meder
[29]
WBRT WBRT 18 Gy in 3 fr 216 KPS >30, Age 670 y, life expectancy >4 w n.a. n.a. NS
WBRT WBRT 18 Gy in 3
fr + (18 Gy in 3 fr or
25 Gy in 10 fr)
6-month
survival
rate
Priestman
[30]
WBRT WBRT 12 Gy in 2 fr 533 ECOG PS <4, MRC neurologic status <4 n.a. NS 17%
WBRT WBRT 30 Gy in 10 fr 25%
Murray [31] WBRT WBRT 54.4 Gy in 34 fr
b.i.d.
445 KPS P70, neurologic function classes 1
or 2
n.a. n.a. NS
WBRT WBRT 30 Gy in 10 fr
Time to retreatment
Davey [32] WBRT WBRT 20 Gy in 5 fr 90 ECOG PS <3, life expectancy >6 w 14 w n.a. NS
WBRT WBRT 40 in 20 fr b.i.d. 32 w
Graham [33] WBRT WBRT 20 Gy in 4 fr 113 ECOG PS <3, life expectancy >8 w 36% 52% NS
WBRT WBRT 40 in 20 fr b.i.d 56% 32%
WBRT, whole brain radiotherapy; fr, fractions; b.i.d., twice a day; w, weeks; m, months; y, year; n.a., not available; NS, not statistically signiﬁcant difference; Neurologic
function class I, able to work, neurologic ﬁndings minor or absent; class II, able to be at home although nursing care may be required. Neurologic ﬁndings present but not
serious; class III, requiring hospitalization and medical care with major neurologic ﬁndings; class IV, requiring hospitalization and in a serious physical or neurological state.
172 Randomized trials in brain metastasesirradiation schedules (10 Gy in a single fraction in the ﬁrst study or
12 Gy in two fractions in the second one) [26]. No differences in re-
sponse rate, morbidity, or survival were found, but time to progres-
sion was shorter for patients receiving short course irradiation in
both the studies. The authors concluded that these ultrashort
high-dose radiation schedules may not be so effective as higher
dose schedules.
A third RTOG study was conducted between 1976 and 1979:
this trial investigated the use of a higher dose scheme (50 Gy in
4 weeks) compared with 30 Gy in 2 weeks in a highly selected
favorable subgroup of patients with brain metastases [27]. Even
in this relatively good-prognosis patient population, 30 Gy in
2 weeks was found to be as effective as higher doses (palliation
of symptoms, rate of clinical improvement, time to progression,
cause of death, and survival were not inﬂuenced signiﬁcantly by
the treatment group).
The RTOG 7916 trial randomized 779 patients to four treatment
arms: 3 Gy  10 fractions with or without misonidazole vs.
5 Gy  6 fractions with or without misonidazole [28]. A total of
393 patients who did not receive misonidazole were analyzed.
Fractionation schedule did not show any statistical signiﬁcance
in terms of survival, time to deterioration of KPS, neurological
death rate, and retreatment for brain disease rates.A French trial compared patients treated with one course of
WBRT (18 Gy in three fractions) with cases treated with two
courses of radiotherapy (18 Gy in three fractions followed by
18 Gy in three fractions or 25 Gy in 10 fractions) [29]. The treat-
ments were equivalent in terms of survival, change of KPS score,
duration of clinical improvement or stabilization, and presence of
neurological symptoms at 6 months of follow-up. No neurologic
complication was observed.
The Royal College of Radiologists Trial [30] compared twoWBRT
schedules (30 Gy in 10 fractions vs. 12 Gy in two fractions on con-
secutive days) in 533 patients. Response rate, median time to re-
sponse, median duration of response, and neurological death rate
did not statistically differ between the two treatment arms. A
slight but statistically signiﬁcant advantage in terms of survival
for the 10-fraction schedule was found (p = 0.04). The reported side
effects (drowsiness, headache, nausea/vomiting, dizziness/ataxia,
cerebral hemorrhage, blurred vision, and ﬁts) did not differ be-
tween the two treatment arms (8% for the 10-fraction vs. 12% for
the two-fraction schedule).
In the RTOG 91.04 trial [31], 445 patients were randomized be-
tween receiving 30 Gy in 3 Gy fractions or accelerated hyperfrac-
tionation (32 Gy to the entire brain plus 24.4 Gy to a boost ﬁeld,
in 1.6 Gy fractions b.i.d.) without any signiﬁcant difference in
Table 5
Trials comparing WBRT vs. WBRT + systemic therapy.
Author Treatment arms n Inclusion criteria Response
rate
Brain
control
Neurologic
death rate
Survival
Komarnicky [28] WBRT WBRT: 30 Gy in 6 or 10 fr 779 All the primaries n.a. n.a. NS NS
WBRT + Misonidazole WBRT: 30 Gy in 6 or 10 fr
Misonidazole 10–12 mg/m2
All Breast +NSCLC All Breast
Suh [34] WBRT WBRT: 30 Gy in 10 fr 515 Single or multiple lesions;
all the primaries
NS 41.0% NS NS NS 4.5 m
WBRT + Efaproxiral
(RSR13)
WBRT: 30 Gy in 10 fr 54.0% 9.0 m
RSR13 75 or 100 mg/Kg/d
Time to progression
All NSCLC All NSCLC
Mehta [35] WBRT WBRT: 30 Gy in 10 fr 401 Single or multiple lesions;
all the primaries
NS NS 5.5 m NS 51.4%
WBRT + Motexaﬁn
Gadolinium (MGd)
WBRT: 30 Gy in 10 fr 3.7 m 36.4%
MGd 5 mg/Kg/d
Time to progression
All WBRT within 28 d
Mehta [36] WBRT WBRT: 30 Gy in 10 fr 554 Single or multiple lesions;
NSCLC as primary tumor
n.a. NS 8.8 m n.a NS
WBRT + Motexaﬁn
Gadolinium (MGd)
WBRT: 30 Gy in 10 fr 24.2 m
MGd 5 mg/Kg/d
Time to progression
All NSCLC All NSCLC
Antonadou [37] WBRT WBRT: 30 Gy in 10 fr 134 All the primaries 33.3.% NS 6.0 m NS 28% NS
WBRT + Temozolomide
(TMZ)
WBRT: 30 Gy in 10 fr 53.4% 7.5 m 13%
Concomitant TMZ 75 mg/m2/d +
Sequential TMZ 200 mg/ m2/d for 5 d
every 28 for 6 cycles
Guerrieri [38] WBRT WBRT: 20 Gy in 5 fr 43 Single or multiple lesions;
NSCLC as primary tumor
NS n.a. n.a NS
WBRT + Carboplatin
(CBDCA)
WBRT: 20 Gy in 5 fr
CBDCA 70 mg/m2/d Progression Free
Survival
Neuhaus [39] WBRT WBRT: 40 Gy in 20 fr 96 Single or multiple lesions;
lung as primary tumor
NS NS n.a. NS
WBRT + Topotecan WBRT: 40 Gy in 20 fr
Topotecan 0.4 mg/ m2/d
Progression Free
Survival
Knisely [40] WBRT WBRT: 37.5 Gy in 15 fr 183 Multiple lesions; all the
primaries
n.a NS n.a. NS
WBRT + Thalidomide WBRT: 37.5 Gy in 15 fr
Thalidomide during WBRT 200–600
mg/d followed by post-RT therapy for a
maximum of 2 y
WBRT, whole brain radiotherapy; fr, fractions; m, months; y, years; n.a., not available; NS, not statistically signiﬁcant difference; NSCLC, not small cell lung cancer.
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late toxicity.
More recently, two trials compared the same accelerated sche-
dule (40 Gy in 20 fractions b.i.d.) with a hypofractionated schedule
(20 Gy in four or ﬁve daily fractions). In both of these trials the
eligibility criteria selected patients with relatively good prognosis.
Davey et al. [32] failed to demonstrate an overall survival beneﬁt
for accelerated WBRT over hypofractionated treatment (p = 0.418).
Patients included in theacceleratedarmhada longer time to retreat-
ment for intracranial relapse (p = 0.03). There was no difference in
terms of toxicity and in terms of functional autonomy (measured
with Barthel index score). The recently published Australian trial
[33] enrolled 113 patients with stable extracranial disease or with
newly diagnosed primary cancer with brain metastases. This trial
also stated that intracranial disease control was improved in the
accelerated schedule (median interval to CNS progression,
9.3 months for patients treated with accelerated WBRT vs.
5.1 months for patients treated with 20 Gy in 5 Gy fractions).
Patients included in the accelerated arm had signiﬁcant advantages
also in terms of death from CNS progression rate (p = 0.03), whereas
the median survival did not signiﬁcantly differ between the two
arms (6.1 vs. 6.6 months,p = 0.17). Late toxicity >G2wasuncommon
(accelerated fractionation arm, n = 2; hypofractionation arm, n = 1).
It may be concluded that despite the extreme heterogeneity in
the fractionation schedules, none of the trials demonstrated a
meaningful improvement of survival, palliative effect, or toxicity.
Available data suggest avoiding ultra-rapid high-dose treatment.
Two trials reported some advantages in terms of intracranial con-
trol when accelerated fractionation was used, suggesting that this
schedule could be considered for the subgroups of patients with
better prognosis.
WBRT alone vs. WBRT and systemic therapy (Table 5)
The already cited RTOG-7916 trial failed to demonstrate any
signiﬁcant advantage from the addition of misonidazole, a hypoxic
cell radiosensitizer, to WBRT [28]. Speciﬁcally, misonidazole did
not improve survival, cause of death, percent of brain retreatment,
or median time to the deterioration of KPS.
Efaproxiral (RSR13) is a modiﬁer of hemoglobin that leads to a
reduction in hemoglobin oxygen-binding afﬁnity, resulting in en-
hanced tumor oxygenation and radiation sensitivity. In the RT009
trial, Suh et al. [34] tested the hypothesis that adding efaproxiral
toWBRT would improve survival in patients with brain metastases.
There were no differences between the two arms in terms of sur-
vival (p = 0.16), time to brain progression (p = 0.21), and proportion
of death caused by neurologic progression (p = 0.46). A signiﬁcant
beneﬁt in terms of response rate was shown in the efaproxiral
arm for breast cancer patients and for non-small cell lung cancer
(NSCLC) patients (p = 0.01), whereas a signiﬁcant effect on survival
was observed only in patients with breast cancer (p = 0003).
An RCT was designed to determine whether the addition of
motexaﬁn gadolinium (MGd) would improve the outcome of
WBRT [35]. MGd is a drug that disrupts redox-dependent path-
ways by targeting oxidative stress-related proteins. More than
60% of the 401 enrolled patients had CNS metastases from NSCLC.
Only among the NSCLC patients were there some beneﬁts in terms
of time to neurological progression (p = 0.04) and in terms of neu-
rological death rate (p = 0.03). Furthermore, a favorable trend in
time to loss of functional independence, measured by the Barthel
Index, was found for NSCLC patients (HR 0.73). Some years later,
the same authors published the results of a second trial, designed
to conﬁrm the beneﬁts of MGd in patients with brain metastases
from NSCLC [36]. The intent-to-treat analysis of 554 patients
showed a rather large trend favoring the MGd group in the time
to neurological progression (WBRT arm, 10.0 months;WBRT + MGd arm, 15.4 months); this difference did not reach the
statistical signiﬁcance (p = 0.12). The authors found that treatment
delay was the major negative variable associated with inferior out-
comes: a signiﬁcant MGd beneﬁt in terms of neurological progres-
sion was seen in all the patients enrolled within 28 days of brain
metastasis diagnosis (p = 0.038).
The results of an RCT that assessed WBRT plus temozolomide
(TMZ) vs. WBRT were published only as an abstract from the AS-
TRO 2002 meeting proceedings [37]. The addition of TMZ resulted
in a better response rate (p = 0.04), without any difference in sur-
vival. Only in the subgroup of NSCLC (n = 108) did patients treated
with WBRT + TMZ also have a lower risk of neurologic death
(p = 0.03) and a longer time to progression (p = 0.01). It has to be
noted that this series has never been published in full-text format.
There are two further RCT that assessed the addition of chemo-
therapy (carboplatin [38] in brain metastases from NSCLC and
topotecan [39] in CNS lesions from NSCLC or SCLC) and one trial
that evaluated the combination of WBRT with antiangiogenic ther-
apy (thalidomide [40]). None of these RCT provided any beneﬁt.
It may be concluded that the few positive data regarding the use
of adding systemic therapy to WBRT are limited to NSCLC and
breast cancer. A beneﬁt in terms of survival was only reached in
breast cancer patients treated with efaproxiral. In patients with
NSCLC, better results in terms of intracranial control can be ob-
tained with the addition of motexaﬁn gadolinium.Randomized controlled trials that assessed the neurocognitive
function and quality of life (Table 6)
The potential neurocognitive morbidity of treatment remains a
poorly understood concern. Quality of life and/or neurocognitive
outcomes were assessed in a number of randomized trials
[11,16,20,22–24,33,36,41–46].
Only three of these trials [16,36,42] used standardized batteries
of neurocognitive tests exploring the main domains of neurofunc-
tion. Four trials [22,41,44,45] used the Mini Mental Status Exami-
nation (MMSE) to measure neurological impairment, although it
has been suggested that this test has low speciﬁcity and sensitivity
[47]. Quality of life was assessed by questionnaires on physical,
psychological, social and symptom domains [11,22–24,33,
43,44,46]. A common concern in these analyses was the patient
drop-off when having to comply with the completion of question-
naires and detailed tests during follow-up. Another problem was
that most of the studies did not include data about other factors
inﬂuencing neurocognitive performance (i.e., chronic use of
steroids and antiepileptic drugs).
Among the trials that assessed the efﬁcacy of surgery in addi-
tion to WBRT, only the Canadian trial [11] reported data regarding
quality of life assessment. The mean Spitzer Quality of Life Index
score was not signiﬁcantly different for a period of up to 6 months
between patients treated with WBRT alone and those treated with
combined treatment (S + WBRT). In the recently published
Australian trial that compared RS + WBRT with S + WBRT [24],
quality of life was assessed using EORTC QOL-C30 and brain cancer
module BN20. No differences were found between the two arms
about 2 months after starting treatment in the 14 patients who
completed the questionnaires. There were too few evaluable
patients for analysis thereafter.
Two studies reported the neurocognitive outcome of patients
randomized between different fractionation schedules. More than
350 patients out of 445 cases enrolled in the RTOG 91.04 trial
(30 Gy in 10 fractions vs. 54.4 Gy in 34 fractions twice a day) [31]
wereassessedwithMMSEatbaselineand in the follow-up.Nodiffer-
encewas found in termsofneurocognitiveperformancebetween the
two arms [41]. In the trial by Graham et al. [33], EORTC QOL-C30
Table 6
Trials assessing Quality of life and impairment of neurocognitive function.
Author Treatment
arms
Evaluable/
enrolled
patients
Test/Questionnaires Baseline
impairment
Follow up evaluation Neurocognitive progression by treatment arm Neurocognitive
impairment at
intracranial
progression
Mintz
[11]
WBRT 43/84 SQLI n.a. Monthly for 6 m and, then, every
3 m until death or lost to follow up
NS n.a.
S + WBRT
Roos [24] RS + WBRT 14/21 EORTC QOL-C30, BN-20 n.a 2 and 3 m after starting treatment
and, then, every 3 m until death or
lost to follow up
NS n.a
S + WBRT
Regine
[41]
WBRT 30 Gy
in 10 fr
359/445 MMSE Yes 2 and 3 m after WBRT NS Yes
WBRT
54.4 Gy in
34 fr
Graham
[33]
WBRT 20 Gy
in 5 fr
93/113 EORTC QOL-C30 Yes Monthly for 12 m and every 2 m
until 24 m and, then, every 5 m
until 60 m
NS n.a.
WBRT 40 Gy
in 20 fr b.i.d.
Meyers
[42]
WBRT 401/401 HVLT-R, Trail Making Test,
COWA, Pegboard test
Yes Monthly for 6 m and, then, every
3 m until death or lost to follow up
NS Yes
WBRT +
Motexaﬁn
Gadolinium
Mehta
[36]
WBRT n.a./554 HVLT-R, Trail Making Test,
COWA
n.a. Monthly for 8 m and, then, every
2 m until death or lost to follow up
NS n.a.
WBRT +
Motexaﬁn
Gadolinium
SQLI scores over the ﬁrst 6 m Quality
Adjusted
Survival
Scott [43] WBRT 106/515 SQLI Yes WBRT day 10, 1 m after WBRT,
and, then, every 3 m until death or
lost to follow up
p = 0.019 p = 0.001 n.a.
WBRT +
Efaproxiral
Corn [44] WBRT 156/183 SQLI, MMSE Yes End of WBRT, 4 m and 6 m after
treatment
NS n.a.
WBRT +
Thalidomide
Improvement @ 6 w assessment Improvement
@ 6 m
assessment
Muacevic
[23]
RS 48/64 EORTC QOL-C30, BN-20 n.a. 6 w and 6 m after treatment p < 0.05 NS Yes
S + WBRT
Time to neurocognitive deterioration
Aoyama
[45]
RS 92/132 MMSE Yes 1 and 3 m after treatment, and,
then, every 6 m until death or lost
to follow up
6.8 m Yes
RS + WBRT 13.6 m
Deterioration in HVLT-R total recall
Chang
[16]
RS 58/58 FACT-BR, HVLT-R, WAIS III,
Trail Making Test, COWA,
Pegboard test
Yes 4 m after treatment 20% n.a.
RS + WBRT 64%
(continued on next page)
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176 Randomized trials in brain metastasesquestionnaireswere administered to the patients. Quality of lifewas
not impaired by the hyperfractionated treatment.
Patients who were included in four different trials assessing the
addition of systemic drugs to WBRT [34–36,40], were evaluated for
neurocognitive and/or quality of life outcomes. In the analysis of
standardized neurocognitive tests performed on 401 patients who
were enrolled in the ﬁrst MGd trial [35], Meyers et al. did not ﬁnd
any signiﬁcant difference in terms of neurocognitive progression
[42]. Anyway, this trial pointed out some important issues. First,
the authors found that more than 90% of patients with brain
metastases had impairment of one or more neurocognitive tests at
baseline. Second, the authors showed that tumor volume strongly
correlates with severity of neurocognitive deﬁcits. Third, patients
with radiologic evidence of progressive disease had greater median
changes in scores for each neurocognitive test. In other words, this
study conﬁrmed the baseline deterioration and stated that brain
progression would be the most important factor in determining
cognitive impairment. In themost recent trial onMGd [36], detailed
tests exploring the main cognitive domains were administered to
patients. The interval of neurocognitive progression was prolonged
in the overall study population (HR 0.78) even though statistical
signiﬁcance was not reached (p = 0.057). The quality of life of a
subgroup of 106 breast cancer patients that had been randomized
into RT009 trial [34] was assessed with baseline Spitzer Quality of
Life Index. Both quality of life and quality-adjusted survival were
improved in the WBRT plus efaproxiral arm compared with the
WBRT alone arm [43]. Finally, Corn et al. [44] analyzed quality of life
and neurologic performance in patients enrolled in the RTOG 0118
trial, where WBRT was compared with WBRT plus thalidomide
[40]. No differences between the two treatment arms were shown
based on either the Spitzer Quality of Life Index or the MMSE.
Moreover, ﬁve RCT compared the neurocognitive outcome in
patients who received local treatment with the neuroperformance
of patients who received local treatment plus WBRT. These trials,
in other words, are of utmost importance to assess the putative role
of WBRT in deteriorating the cognitive function of patients with
brain metastases. In the German trial that compared exclusive RS
with postoperativeWBRT [23], better scores for the role functioning
domain and for quality of life were found 6 weeks after treatment
for patients treated with RS. This difference was lost 6 months after
the treatment. In the prematurely closed randomized Trans-Tasman
RadiationOncologyGroup trial [22], despite the small numberof en-
rolled patients, the authors found that upfrontWBRT did not cause a
deterioration inMMSE or in overall quality of life, as measuredwith
the EORTC QOL-C30 questionnaire. The neurocognitive MMSE-
based assessment of patients included in the Japanese trial pub-
lished by Aoyama et al. [15] was reported by the same authors
[45]. Time to neurocognitive deterioration was marginally pro-
longed in patients who received combined treatment (p = 0.05). Of
note, patients treated with RS + WBRT did signiﬁcantly better in
the ﬁrst month of follow-up. Among patients who survived longer,
the neurocognitive performance of patients treatedwith RS +WBRT
was worse than that of patients treated exclusively with radiosur-
gery. This study conﬁrms that the addition of WBRT protected pa-
tients from an early recurrence and, consequently, from an early
deterioration of cognitive function. Otherwise, the long-term ad-
verse effects of radiation therapy could be not negligible and could
explain theworst outcome in the longer survivors. In the already ci-
ted trial by Chang et al. [16], patients treated with RS + WBRT had a
signiﬁcant impairment in learning and memory function as mea-
sured with the Hopkins Verbal Learning Test – Revised total recall
at 4 months. Although a formal neurocognitive testing was
scheduled at baseline and at each follow-up visit, the trial has been
strongly criticized for the timing of the neurocognitive evaluation:
the primary endpoint of cognitive function was indeed assessed at
a single time point of 4 months [17,18]. A temporary drop-off of
S. Scoccianti, U. Ricardi / Radiotherapy and Oncology 102 (2012) 168–179 177neurocognitive function has been shown for somemonths after the
end of radiation treatment [48]; the lack of a conﬁrmed signiﬁcant
difference in long-term follow-up is a meaningful shortcoming of
this study. Furthermore, the signiﬁcant imbalance of the study
groups in terms of brain disease volume could explain the worse
cognitive outcome in the combined treatment arm. Patients en-
rolled in the EORTC 22285–26001 trial [21] were evaluated with
the EORTC QOL-C30 BN20 questionnaire to assess the effects of
adjuvant WBRT [46]. Differences in role functioning, emotional
function, and fatigue were not signiﬁcant. Conversely, some signiﬁ-
cant differences were found for global health-related quality of life,
cognitive function, and physical ability. Something noteworthy is
that these differences reached clinical relevance (i.e., P10 points
of difference) only in some speciﬁc timepoints during the follow-up.
Therefore, it may be concluded that nearly all patients with
brain metastases have some degree of baseline neurocognitive
impairment, whereas brain progression is the most important fac-
tor in determining cognitive deterioration. To our knowledge,
based on the few existing data, the neuroperformance of the pa-
tients is not impaired by the addition of surgery to WBRT or by
the different WBRT fractionation (at least for what concerns the
schedules used in the trials above). Efaproxiral appeared to im-
prove the quality of life of patients with brain metastases from
breast cancer who were treated with WBRT. Although the evidence
of WBRT-related neurotoxicity of a clinically signiﬁcant degree is
arguable, the risk of long-term effects of WBRT on neurocognitive
function cannot be excluded.
Future directions
There are ﬁve major areas of future investigation. First, we need
to improve the outcome of WBRT by adding new radiosensitizers
or targeted agents. Second, methods to reduce the potential neuro-
toxicity of the treatment should be evaluated. Intensity-modulated
whole-brain irradiation with the avoidance of areas where neural
stem cells are located (hippocampus and subependymal areas)
could be offered to highly selected patients to reduce the risk of
neurocognitive radiation-induced damage [49,50]. The estimated
risk of disease progression within the avoidance region related to
such approach is reasonably low [51]. Third, a recently published
systematic review [52], assessing the dose–effect relationship in
stereotactic radiotherapy (SRT), showed that, assuming an a/b va-
lue of 12 Gy for brain metastases, a biologically effective dose
(BED) of at least 40 Gy is necessary to achieve a 12-month local
control rate of >70%. A BED12 value of 40 Gy translates into a single
fraction of 20 Gy, 2 fractions of 11.6 Gy, or three fractions of 8.5 Gy.
These data need to be conﬁrmed in prospective trials that explore
appropriate dosage for safe and effective SRT for radiosurgery and,
even more, for hypofractionated stereotactic radiotherapy, the
dose–effect prospective data being even more scarce for the latter
[53]. Fourth, another important point to explore is to assess the
possibility to deliver synchronous boost treatments to multiple
targets concurrent with WBRT, without the need for separate ste-
reotactic procedures [54]. Last, further conﬁrmation of perfor-
mance of the frameless image-guided radiosurgery system for
various patient anatomies, isocenter localizations and immobiliza-
tion systems are needed [55,56].
Conclusions
RCT in oligometastatic patients
WBRT vs. S + WBRT
The combined treatment may improve local control [8] and may
prolong time to neurologic death [8]. Survival beneﬁt from theaddition of surgery may exist but it is more pronounced for better
prognosis patients [8–10].
WBRT vs. RS + WBRT
The addition of radiosurgery may improve local control [12,13]
but it also might prolong time to any brain failure [12]. A slight
improvement in survival may be obtained in patients with single
brain lesions [13].
S vs. S + WBRT
Patients who receive WBRT may have a better brain tumor con-
trol [14,20,21] both in terms of local control and freedom from new
brain metastases [14,20,21]. The addition of WBRT may reduce
neurologic death rate [14,20,21] but it does not alter the survival
rate [14,20–22].
RS vs. RS + WBRT
Upfront WBRT may decrease brain recurrence [15,16,20,21]
both in terms of better local tumor control rate [15,16,20,21] and
improved distant brain tumor control rate [15,16,20,21]. Neuro-
logic death rate may be reduced [20,21] in patients treated with
the combined treatment, but no survival beneﬁt is reached
[15,16,20–22].
S + WBRT vs. RS + WBRT
There is no evidence of superiority of a combined treatment
over the other one [24] but no deﬁnitive conclusions can be made
in this regard because only a small, prematurely closed trial was
undertaken.RCT addressing the point of improving WBRT outcome
Comparison of different WBRT fractionation schedules
Different fractionation schemes do not show any statistical sig-
niﬁcance in terms of brain tumor control [25,27,28], neurologic
death rate [27,28] and survival [25,27–29,31]. Ultrashort high-dose
radiation schedules are not recommended because of worse results
[26,30] and because of increasing risk of neurotoxicity. Accelerated
WBRT may improve intracranial control in patients with favorable
prognostic factors [32,33].
WBRT alone vs. WBRT and systemic therapy
The addition of efaproxiral to WBRT may improve survival in
patients with brain metastases from breast cancer [34]. In patients
with NSCLC, better results in terms of brain tumor control and re-
duced neurologic death rate may be obtained with the addition of
motexaﬁn gadolinium [35].RCT that assessed neurocognitive impairment and quality of life
Baseline cognitive impairment is frequently reported
[16,33,41–46]. Intracranial disease progression is a strongly signif-
icant factor in worsening neurocognitive performance
[23,41,42,45]. Some degrees of neurocognitive impairment [16]
and deterioration of quality of life [46] have been reported in pa-
tients who received the addition of WBRT to the local treatment.
Efﬁcacy of WBRT in improving intracranial tumor control seems
to be stronger than the evidence of a clinically signiﬁcant neuro-
toxicity related to brain irradiation. Impairment of both neurocog-
nitive function and quality of life in patients with brain metastases
needs to be further addressed in RCT, using standardized cognitive
testing and questionnaires. Furthermore, adequate correlation of
clinical signs of neurocognitive impairment with imaging assess-
ment during follow up should be provided.
178 Randomized trials in brain metastasesNew generation of RCT will be necessary to clarify the role of
new techniques (frameless stereotactic radiosurgery, WBRT with
concomitant boost) and new systemic treatments.References
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